| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03035357 Details | 2017-04-21 Interventional | 2 | 0 | Daratumumab Genital Neoplas… Neoplasms Prostatic Neopl… Malignant Neopl… Prostate Cancer | PI's Request - | |||
| NCT02319265 Details | 2017-04-21 Interventional | 1/2 | 0 | Melatonin Sepsis Toxemia | Study registered elsewhere and is not covered by FDA - | |||
| NCT00708799 Details | 2017-04-21 Interventional | 2 | - | Azithromycin Sepsis Systemic Inflam… | Safety evaluation due to recent publications. - | |||
| NCT00397501 Details | 2017-04-21 Interventional | 1/2 | 0 | Carboplatin Methotrexate Sodium thiosulf… Trastuzumab Breast Neoplasm… Central Nervous… Drug-Related Si… Nervous System … Brain and Centr… Breast Cancer Cognitive/Funct… Drug/Agent Toxi… Psychosocial Ef… | after original approval, IRB closed enrollment; major revisions required to re-open. - | |||
| NCT00346151 Details | 2017-04-21 Interventional | 2 | 5 | Abatacept Antilymphocyte … Glucocorticoids Immunoglobulins Methylprednisol… Sirolimus Thymoglobulin Renal Transplan… | Stopping rule-acute rejection threshold-was met based on local biopsy results The trial was stopped early due to meeting an acute rejection threshold of three acute rejections based on local pathology reads in the first five participants enrolled. | |||
| NCT00238173 Details | 2017-04-21 Interventional | 1 | 2 | Acetylcysteine Carboplatin Cyclophosphamid… Etoposide Etoposide phosp… Mannitol N-monoacetylcys… Sodium thiosulf… Brain Neoplasms Central Nervous… Drug-Related Si… Nervous System … Bone Marrow Sup… Brain and Centr… Drug/Agent Toxi… Long-term Effec… | OHSU IRB closed study to further enrollment 2/17/2006 - | |||
| NCT02520102 Details | 2017-04-20 Interventional | 2 | 0 | Sargramostim Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Company has fulfilled post-marketing requirements - | |||
| NCT01977339 Details | 2017-04-20 Interventional | 4 | 0 | Bupivacaine Total Knee Arth… | New departmental administration, loss of key study faculty - | |||
| NCT01715311 2012-001536-59 Details | 2017-04-20 Interventional | 4 | 0 | Tiotropium Brom… Lung Diseases Lung Diseases, … Pulmonary Disea… Chronic Obstruc… | withdrawn prior to patient recruitment - | |||
| NCT00978146 Details | 2017-04-20 Interventional | 2 | 0 | Hydroxyurea Fibroma Fibromatosis, A… Desmoid Tumors Fibromatosis | Study was administratively withdrawn by the IRB; no subjects were enrolled - | |||
| NCT00955474 Details | 2017-04-20 Interventional | 4 | 32 | Citalopram Escitalopram Quetiapine Fuma… Sertraline Depression Depressive Diso… Depressive Diso… Mental Disorder… Psychotic Disor… Major Depressiv… | AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012 - | |||
| NCT01758458 Details | 2017-04-19 Interventional | 1/2 | 4 | Aldesleukin Interferon-beta Interferons Interleukin-2 Carcinoma Carcinoma, Merk… Recurrent Merke… Stage IV Merkel… | A Phase I/II study (NCT01758458) is now recruiting - | |||
| NCT00886743 Details | 2017-04-19 Interventional | 2 | 19 | Oprelvekin Thrombocytopeni… Severe Thromboc… | Business reason, Pfizer's requested withdrawal of the Biologics License Application (BLA) .
This study is not being discontinued for efficacy or safety reason - | |||
| NCT03117855 Details | 2017-04-18 Interventional | 1 | 0 | Capecitabine Carcinoma, Duct… Cholangiocarcin… Bile Duct Adeno… Stage III Intra… Stage IVA Intra… Stage IVB Intra… | Company no longer interested in supporting this trial - | |||
| NCT01750762 Details | 2017-04-18 Interventional | 1 | 1 | Lenalidomide Multiple Myelom… Lymphoma | - - | |||
| NCT00879970 Details | 2017-04-18 Interventional | 4 | 1332 | Pioglitazone Rosiglitazone Vitamin D Diabetes Mellit… | FDA has placed the trial on full clinical hold. The intended duration of this study was approximately 5.5 years. However, the trial was stopped prematurely because of regulatory concerns after a mean of 162 days without consideration of the accrued data. | |||
| NCT02721277 Details | 2017-04-17 Interventional | 1/2 | 2 | SMOFlipid Cholestasis Jaundice Jaundice, Obstr… | - - | |||
| NCT01409993 Details | 2017-04-17 Interventional | 4 | 78 | Sildenafil Citr… Glucose Intoler… Impaired Glucos… | Aim 1 was stopped by DSMB. Aim 2 was stopped due to ending of funding. - | |||
| NCT01267240 Details | 2017-04-14 Interventional | 2 | 25 | Capecitabine Vorinostat Carcinoma Carcinoma, Squa… Recurrence Squamous Cell C… Paranasal Sinus… Recurrent Hypop… Recurrent Laryn… Recurrent Oral … Recurrent Oroph… Stage IVA Hypop… Stage IVA Laryn… Stage IVA Oral … Stage IVA Oroph… Stage IVB Hypop… Stage IVB Laryn… Stage IVB Oral … Stage IVB Oroph… Stage IVC Hypop… Stage IVC Laryn… Stage IVC Oral … Stage IVC Oroph… | Study treatment did not show clinical activity. Early termination due to lack of activity of study drug. | |||
| NCT00642616 Details | 2017-04-14 Interventional | 3 | 34 | Insulin Asthma Diabetes Mellit… Diabetes Mellit… Diabetes Mellit… Lung Diseases Lung Diseases, … Pulmonary Disea… Moderate Chroni… Type 1 Diabetes… Type 2 Diabetes… | Terminated upon recommendation of the Data Safety Monitoring Board (DSMB) - Early termination of trial leading to small numbers of subjects analyzed |